Value of Life Sciences Innovation
Other featured articles
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Targeted Therapies Linked to Improved Outcomes for Advanced-Stage Breast Cancer Patients
Targeted therapies accounted for about 90% of new active substance approvals in oncology between 2011 and 2018.
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
This Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.